Functional Health Panel (Female)

The CBC quantifies the three primary formed elements of blood — erythrocytes, leucocytes, and thrombocytes — alongside derived indices reflecting erythrocyte size and haemoglobin content. Whole blood is collected into EDTA anticoagulant to prevent clotting. The differential provides the proportional and absolute distribution of leucocyte subtypes (neutrophils, lymphocytes, monocytes, eosinophils, basophils), which characterise the immune and inflammatory state. Erythrocyte indices — MCV, MCH, MCHC — are computed from the primary cell counts and haemoglobin measurement.

The CBC is the foundational haematological screen in any comprehensive health panel, providing simultaneous assessment of anaemia type and severity, infection or inflammatory leucocytosis, leucopenia suggesting immunosuppression or bone marrow suppression, and thrombocytopenia or thrombocytosis. In females specifically, haemoglobin, haematocrit, MCV, and MCH are critical for iron deficiency anaemia screening — the most prevalent nutritional deficiency in premenopausal women — and for monitoring haematological status in the context of menstrual blood loss.

The CMP evaluates three organ systems simultaneously: hepatic function (ALT, AST, ALP, bilirubin, total protein, albumin — reflecting synthetic, metabolic, and excretory hepatocyte function); renal function (creatinine, BUN, eGFR — reflecting glomerular filtration and tubular handling); and basic metabolic status (glucose, calcium, sodium, potassium, chloride, bicarbonate — reflecting electrolyte homeostasis and glucose regulation). Albumin serves dual roles as a marker of hepatic synthetic function and nutritional status.

The CMP provides simultaneous first-pass screening across hepatic, renal, metabolic, and nutritional domains within a single specimen. In functional health panels, the CMP anchors the biochemical safety baseline — identifying hepatic enzyme elevation from fatty liver disease or medication effect, renal impairment affecting drug dosing and metabolic clearance, glucose dysregulation preceding frank diabetes, and hypoalbuminaemia indicating chronic inflammatory or nutritional compromise. Sex-specific reference ranges for creatinine and ALT are critical for female patients, as standard laboratory upper limits derived from male-predominant populations overestimate normal female values.

TSH is a glycoprotein hormone secreted by the anterior pituitary in response to hypothalamic thyrotropin-releasing hormone (TRH) and regulated by negative feedback from circulating thyroid hormones. It is the primary regulator of thyroid gland function — stimulating T4 and T3 synthesis and secretion — and is the most sensitive indicator of central-peripheral thyroid hormone balance, rising before free thyroid hormone levels become abnormal in early hypothyroidism.

TSH is the first-line thyroid screening marker in any comprehensive health panel and the most sensitive indicator of subclinical thyroid dysfunction. It is indispensable in female health panels given the substantially higher prevalence of thyroid autoimmune disease and hypothyroidism in women — particularly perimenopausal and postmenopausal women — and the significant metabolic, cardiovascular, reproductive, and psychological consequences of untreated thyroid dysfunction.

Free T4 is the unbound, biologically available fraction of total thyroxine, representing approximately 0.02–0.04% of the total T4 pool. It reflects direct thyroid secretory output, uninfluenced by changes in thyroid binding globulin (TBG) — which is elevated by oestrogen and therefore particularly relevant in female patients on oral contraceptives or hormone replacement therapy, where TBG elevation would artefactually raise total T4 without affecting Free T4.

Free T4 is the standard tier-two thyroid marker in panels with TSH, confirming the nature and severity of thyroid dysfunction identified on TSH screening. In female health panels, Free T4 is essential given the prevalence of oestrogen-driven TBG changes that render Total T4 unreliable. Reduced Free T4 with elevated TSH confirms primary hypothyroidism; normal Free T4 with elevated TSH indicates subclinical hypothyroidism; low-normal Free T4 with normal-low TSH in a symptomatic patient raises concern for central hypothyroidism or non-thyroidal illness.

Free T3 is the biologically active thyroid hormone that directly mediates intracellular metabolic effects via nuclear thyroid hormone receptors. Approximately 80% of circulating T3 is generated by peripheral deiodination of T4 by deiodinase enzymes (DIO1, DIO2) in liver, kidney, and other tissues, rather than direct thyroid secretion. Selenium is an essential cofactor for deiodinase function. T3 has a shorter half-life (approximately 1 day) and higher receptor affinity than T4.

Free T3 is not recommended as a first-line thyroid screening marker by mainstream guidelines but is clinically valuable in functional health panels to identify impaired T4-to-T3 peripheral conversion — a pattern characterised by normal TSH and Free T4 with low-normal Free T3, commonly seen in chronic stress, non-thyroidal illness, selenium deficiency, and certain dietary restriction states. This pattern is a clinical focus in functional and integrative thyroid assessment and represents thyroid dysfunction not captured by TSH and Free T4 alone.

Estradiol is the primary and most potent endogenous oestrogen in premenopausal women, produced predominantly by granulosa cells of developing ovarian follicles under FSH stimulation. It is synthesised via aromatisation of androgens — primarily testosterone — by the enzyme aromatase (CYP19A1). Estradiol fluctuates substantially across the menstrual cycle, peaking at the mid-cycle LH surge and falling sharply at menstruation. In postmenopausal women, circulating estradiol derives primarily from peripheral aromatisation of adrenal androgens in adipose tissue.

Estradiol is the central marker of ovarian follicular function and is essential in the evaluation of menstrual cycle irregularity, ovarian reserve, perimenopausal transition, and hormone replacement therapy monitoring. Low estradiol alongside elevated FSH defines ovarian insufficiency; cycle-phase-appropriate estradiol levels confirm adequate follicular development. In hormone replacement therapy assessment, estradiol guides dosing titration to symptom relief while minimising supraphysiological exposure.

Progesterone is a C21 steroid hormone produced primarily by the corpus luteum following ovulation, with secondary production by the adrenal cortex and, during pregnancy, the placenta. Its synthesis requires cholesterol as substrate and is driven by the post-ovulatory LH surge. Progesterone prepares the endometrium for embryo implantation, suppresses further ovulation, and has anxiolytic effects via conversion to the neurosteroid allopregnanolone. It is metabolised by the liver to pregnanediol, excreted in urine.

Mid-luteal serum progesterone (typically drawn on day 19–22 of a 28-day cycle, or 7 days before anticipated menstruation) is the standard biochemical confirmation of ovulation. Luteal phase progesterone below 3–5 ng/mL suggests anovulation or inadequate corpus luteum function. In perimenopause, declining progesterone precedes oestrogen decline and is associated with sleep disturbance, anxiety, and menstrual irregularity. Bioidentical progesterone therapy monitoring requires careful timing relative to the dosing protocol.

FSH is a gonadotropin secreted by the anterior pituitary under hypothalamic GnRH stimulation. In women, FSH drives follicular development in the ovary during the follicular phase of the menstrual cycle, stimulating granulosa cell proliferation and estradiol production via aromatase induction. As ovarian reserve declines with age, reduced inhibin B feedback causes progressive FSH elevation — the hallmark of diminishing ovarian reserve and perimenopause.

Elevated early follicular phase FSH (day 2–3 of cycle) is the established marker of diminished ovarian reserve and is a core component of fertility workup alongside AMH and antral follicle count. Markedly elevated FSH with low estradiol confirms primary ovarian insufficiency or menopause. Unexpectedly low FSH in the context of irregular cycles may indicate hypothalamic or pituitary suppression from stress, low body weight, or exercise.

LH is a gonadotropin co-secreted with FSH by anterior pituitary gonadotrophs in response to pulsatile GnRH. The mid-cycle LH surge — triggered by rising estradiol through a positive feedback mechanism — drives ovulation by inducing oocyte maturation and luteinisation of the dominant follicle, forming the corpus luteum. LH also stimulates ovarian theca cell androgen production.

LH is interpreted alongside FSH as a ratio in the evaluation of polycystic ovary syndrome (PCOS), where an elevated LH:FSH ratio (typically >2:1) — alongside hyperandrogenism and oligo-ovulation — supports the diagnosis. Elevated LH with elevated FSH in the postmenopausal pattern confirms gonadotropin release following loss of ovarian negative feedback. The LH:FSH ratio is a core interpretive metric in female hormone evaluation rather than either marker in isolation.

Testosterone in women is produced by the ovaries, adrenal cortex, and peripheral conversion from androstenedione in adipose tissue, skin, and other tissues. The majority of circulating testosterone is bound to SHBG and albumin, with only approximately 1–3% in the free, biologically active form. Testosterone levels fluctuate across the menstrual cycle and decline progressively with age and following oophorectomy. Accurate measurement at the low female reference range requires a high-sensitivity assay — ideally LC-MS/MS.

Total testosterone in females is assessed in the evaluation of androgen excess (PCOS, adrenal hyperplasia, androgen-secreting tumour) and androgen deficiency (reduced libido, fatigue, and reduced musculoskeletal function in perimenopausal and postmenopausal women). SHBG must be assessed alongside total testosterone to estimate free androgen availability — elevated SHBG from oestrogen or thyroid hormone effect can reduce free testosterone despite normal total levels.

SHBG is a glycoprotein produced by the liver that binds testosterone and estradiol with high affinity (and DHT with the highest affinity), as well as other steroid hormones with lower affinity. Hepatic SHBG synthesis is upregulated by oestrogens, thyroid hormones, and phytoestrogens, and suppressed by androgens, insulin, and insulin-like growth factor-1 (IGF-1). The SHBG-bound fraction of sex steroids is biologically inactive; only the free and loosely albumin-bound fractions are bioavailable.

SHBG is essential for calculating free androgen index (FAI = [Total Testosterone × 100] ÷ SHBG) and estimating free testosterone bioavailability. In PCOS, suppressed SHBG from hyperinsulinaemia compounds the effect of elevated androgens by increasing the free androgen fraction. In women on oral oestrogen therapy, SHBG is substantially elevated, reducing free testosterone and potentially contributing to androgen deficiency symptoms despite normal total testosterone. SHBG is therefore a critical interpretive adjunct to total testosterone in all female hormone assessments.

DHEA-S is the sulfate ester and primary circulating storage form of DHEA, produced almost exclusively by the adrenal zona reticularis. Its long plasma half-life (7–10 hours versus 1–3 hours for DHEA) and minimal diurnal variation make it the preferred adrenal androgen marker for clinical testing. DHEA-S production declines progressively with age — a process termed adrenarche in reverse — with peak levels occurring in the mid-twenties followed by approximately 2–5% annual decline.

DHEA-S is the primary adrenal androgen precursor and a meaningful contributor to peripheral sex steroid production, particularly in postmenopausal women where adrenal androgen conversion is the dominant source of circulating oestrogen and testosterone. In female health panels, DHEA-S is assessed as a marker of adrenal androgen reserve, adrenal function, and biological ageing. Markedly elevated DHEA-S warrants investigation for adrenal hyperplasia or adrenal tumour. Suppressed DHEA-S alongside clinical fatigue, low mood, and reduced libido is a focus of adrenal support protocols in integrative practice.

25-Hydroxyvitamin D is the major circulating form and the accepted clinical marker of vitamin D status, reflecting both cutaneous synthesis from solar UVB exposure and dietary/supplemental intake. It is produced by hepatic 25-hydroxylation of vitamin D3 (cholecalciferol) and D2 (ergocalciferol) and has a serum half-life of approximately 2–3 weeks — making it a reliable indicator of medium-term vitamin D status rather than acute intake.

Vitamin D deficiency is prevalent across female populations, particularly in those with limited sun exposure, darker skin phototypes, obesity, malabsorption, or exclusively indoor lifestyles. In female health panels, adequate vitamin D is relevant to bone mineral density maintenance, immune regulation, cardiovascular risk, mood and cognitive function, breast and colorectal cancer risk reduction, and fertility outcomes. Measurement is essential before supplementation dosing and for monitoring repletion protocol efficacy.

Ferritin is an intracellular iron storage protein composed of 24 heavy and light chain subunits forming a hollow nanocage capable of storing up to 4,500 iron atoms per molecule. A small fraction of intracellular ferritin is glycosylated and secreted into the circulation — serum ferritin concentrations reflect the total body iron store under stable conditions. Ferritin is also an acute phase reactant, rising proportionally with systemic inflammation independent of iron status — a critical interpretive caveat.

Ferritin is the most sensitive and specific single marker for iron deficiency — falling below normal before haemoglobin, MCV, or serum iron become abnormal, allowing detection of pre-anaemic iron depletion. In premenopausal women with recurrent menstrual blood loss, ferritin is the primary iron status marker for monitoring. Functional medicine practitioners apply substantially higher optimal ferritin targets than the laboratory lower limit — low-normal ferritin in the context of fatigue, hair loss, cold intolerance, or restless legs warrants clinical attention despite being within the reference range.

C-reactive protein is an acute phase pentameric plasma protein synthesised by the liver in response to interleukin-6 (IL-6), interleukin-1β (IL-1β), and TNF-α. The high-sensitivity assay detects CRP at concentrations below 10 mg/L, allowing cardiovascular risk stratification in otherwise healthy individuals at the lower end of the inflammatory spectrum — a range that standard CRP assays cannot reliably quantify. CRP has a short plasma half-life of approximately 19 hours, making it a responsive marker of acute inflammatory changes.

hs-CRP is the validated low-grade systemic inflammation marker for cardiovascular risk stratification in the JUPITER and REYNOLDS Risk Score frameworks. In a female functional health panel, hs-CRP serves dual roles: cardiovascular risk quantification as an independent predictor of major adverse cardiovascular events beyond traditional Framingham risk factors, and a global inflammatory burden marker guiding investigation of occult infection, autoimmune activation, dietary inflammatory load, gut permeability, and adipose-driven chronic inflammation in metabolic syndrome and obesity.

HbA1c reflects the proportion of haemoglobin in erythrocytes that has undergone non-enzymatic glycation in proportion to mean ambient blood glucose concentration over the preceding 8–12 weeks — the approximate lifespan of circulating erythrocytes. The relationship between mean plasma glucose and HbA1c is approximately linear across the clinical range. Conditions that alter erythrocyte lifespan — haemolytic anaemia, iron deficiency anaemia (spuriously elevates HbA1c), haemoglobinopathies — invalidate HbA1c as an accurate glycaemic marker.

HbA1c is the standard long-term glycaemic status marker for diabetes screening, diagnosis, and treatment monitoring. In female functional health panels, HbA1c serves as the integrated carbohydrate metabolism marker — identifying prediabetes well before fasting glucose becomes overtly abnormal, monitoring glycaemic trend in patients on dietary intervention, and providing the glycaemic context for interpreting sex hormone patterns, as insulin resistance drives PCOS-associated androgen excess, SHBG suppression, and ovulatory dysfunction.

Insulin is a 51-amino acid peptide hormone secreted by pancreatic beta cells in response to rising blood glucose, amino acids, and incretin hormones (GLP-1, GIP). In the fasting state, basal insulin secretion maintains hepatic glucose output suppression and prevents lipolysis. Fasting insulin reflects beta cell basal secretory output and, when elevated relative to fasting glucose, indicates peripheral insulin resistance requiring compensatory hyperinsulinaemia to maintain euglycaemia.

Fasting insulin is the functional marker of insulin resistance — a key driver in PCOS, metabolic syndrome, non-alcoholic fatty liver disease, cardiovascular risk, and weight management difficulty. Standard fasting glucose and HbA1c can remain normal while fasting insulin is substantially elevated, representing early insulin resistance that is missed by standard glycaemic markers alone. In female health panels, fasting insulin is critical for characterising the metabolic driver of androgen excess, SHBG suppression, and ovulatory dysfunction in PCOS and premenopausal metabolic syndrome.

The standard lipid panel quantifies the major lipoprotein-associated cholesterol fractions and triglycerides in fasting serum. LDL-C is most commonly calculated via the Friedewald equation (TC − HDL − [TG ÷ 5]) and is unreliable when triglycerides exceed 400 mg/dL. HDL-C is directly measured and is the anti-atherogenic lipoprotein fraction. Non-HDL-C (TC − HDL-C) captures all atherogenic lipoprotein cholesterol and is recommended as a secondary target by current guidelines. Triglycerides are measured directly as a marker of VLDL burden and endogenous lipoprotein metabolism.

The lipid panel provides the foundational cardiovascular risk lipid profile. In female health panels, oestrogen status is a key interpretive context — premenopausal women have naturally higher HDL-C and lower LDL-C relative to men, with this advantage progressively lost after menopause. Oral oestrogen therapy substantially elevates triglycerides through increased hepatic VLDL synthesis — a consideration when assessing lipid panels in women on oral contraceptives or oral HRT. Triglyceride-rich dyslipidaemia with low HDL-C is the cardiovascular lipid signature of insulin resistance and metabolic syndrome in females.

Urinalysis combines chemical dipstick analysis with microscopic examination of a urine centrifugate to assess renal tubular function, glomerular integrity, urinary tract health, and systemic metabolic states reflected in urine composition. Specific gravity and osmolality reflect renal concentrating ability and hydration status. Protein, blood, and cellular casts assess glomerular barrier integrity. Leucocyte esterase and nitrites are bacteriuria and infection markers. Glucose in urine indicates tubular reabsorptive capacity has been exceeded by hyperglycaemia.

Urinalysis provides the renal and urinary tract screen within the comprehensive health panel, identifying proteinuria (early diabetic or hypertensive nephropathy), haematuria (glomerulonephritis, urological pathology), glycosuria (undiagnosed diabetes or renal tubular disorder), and urinary tract infection. In female health panels, urinalysis is particularly relevant given the higher prevalence of recurrent urinary tract infections, and as a companion to creatinine and eGFR in assessing early kidney disease risk in patients with hypertension, diabetes, or autoimmune conditions.